Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Apr 9, 2014 8:35 AM Flag

    Cost of study

    $10M for the NTM study and he said the PH3 or PH4elf-imposed) would only be 3 months (as Pianoman stated) so the cost will not be major. This was a very good presentation and he answered questions quite thorough and honestly.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The cost is not the limitation. What dose, duration of treatment and endpoint will be agreed upon with the FDA so that INSM meets their primary and secondary endpoints? Hopefully Dr. Olivier has some insights that will be written into the Phase III.

      If you look at the one Primary and the other Secondary endpoints, they all say "Safety" after the criteria. I think the NTM study was written as a Phase IIa with the hope that the therapeutic index would be so outstanding that FDA would expedite them to submit an NDA. That is not going to happen as a result of this study. But they did achieve safety.

      We shall see what appears on the horizon in the next 3-4 months.

      GLTASL

      Sentiment: Hold

    • Confidence and conviction.

      Sentiment: Buy

 
INSM
9.72+0.67(+7.40%)Jun 28 4:00 PMEDT